Aileron Therapeutics (ALRN) Hits New 12-Month Low at $9.13

Aileron Therapeutics Inc (NASDAQ:ALRN)’s share price reached a new 52-week low on Friday . The stock traded as low as $9.13 and last traded at $9.62, with a volume of 29800 shares changing hands. The stock had previously closed at $9.83.

A number of institutional investors have recently made changes to their positions in ALRN. Jennison Associates LLC purchased a new stake in Aileron Therapeutics in the 2nd quarter valued at approximately $2,788,000. Sphera Funds Management LTD. acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $1,394,000. Nexthera Capital LP acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $1,272,000. Goldman Sachs Group Inc. acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $418,000. Finally, Laurion Capital Management LP acquired a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at approximately $335,000. Hedge funds and other institutional investors own 7.64% of the company’s stock.

WARNING: This piece of content was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/22/aileron-therapeutics-alrn-hits-new-12-month-low-at-9-13.html.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit